# moderate-to-severe HS FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/moderate-to-severe-hs

> No upcoming FDA catalysts in moderate-to-severe HS; 3 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 2022 | [MoonLake Immunotherapeutics topline data readout](https://sec-api.dev/companies/mltx/catalysts) | MLTX | moderate-to-severe HS | completed, met | "In May 2022, we initiated a Phase 2b trial of SLK in patients with moderate-to-severe HS (the MIRA trial (M1095-HS-201)), and in June 2023, we announced positive top-line results from this trial, which met its primary endpoint of Hidradenitis Suppurativa Clinical Response ("HiSCR") 75." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1821586/000182158625000022/mnlk-20250930.htm)) |
| Jun 2023 | [MoonLake Immunotherapeutics topline data readout](https://sec-api.dev/companies/mltx/catalysts) | MLTX | moderate-to-severe HS | completed, met | "In May 2022, we initiated a Phase 2b trial of SLK in patients with moderate-to-severe HS (the MIRA trial (M1095-HS-201)), and in June 2023, we announced positive top-line results from this trial, which met its primary endpoint of Hidradenitis Suppurativa Clinical Response ("HiSCR") 75 with 43% of patients treated with SLK 120mg achieving such response at week 12." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000007/mnlk-20260331.htm)) |
| Oct 2023 | [MoonLake Immunotherapeutics topline data readout](https://sec-api.dev/companies/mltx/catalysts) | MLTX | moderate-to-severe HS | completed, positive | "In October 2023, we announced positive 24-week top-line results showing that the maintenance treatment with SLK led to further improvements in HiSCR75 response rates and other clinically relevant outcomes in patients with moderate-to-severe HS." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000007/mnlk-20260331.htm)) |

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/moderate-to-severe-hs.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "moderate-to-severe HS FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/moderate-to-severe-hs

```bibtex
@misc{secapidev_indications_moderate_to_severe_hs_20261116,
  title        = {moderate-to-severe HS FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/moderate-to-severe-hs}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_moderate_to_severe_hs_20261116","title":"moderate-to-severe HS FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/moderate-to-severe-hs","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
